POLR2A and cancer: Because hemizygous TP53 deletion is common across many cancer types (Yu et al., 2019; van Kampen et al., 2025), POLR2A is frequently co-deleted, resulting in haploinsufficiency of both genes and creating a potential therapeutic vulnerability (Muller et al., 2012; Nijhawan et al., 2012).